Full-Time
Develops and commercializes prescription medicines
No salary listed
Senior, Expert
Bhubaneswar, Odisha, India
AstraZeneca focuses on discovering, developing, and selling prescription medicines, primarily in three areas: Oncology (cancer), Cardiovascular, Renal & Metabolism (heart and kidney diseases), and Respiratory & Immunology (lung and immune system diseases). Their products are developed through extensive research and development, which includes rigorous clinical trials and regulatory approvals before reaching the market. What sets AstraZeneca apart from competitors is their commitment to collaboration, exemplified by their Open Innovation program that shares resources with the scientific community, and their A.Catalyst Network, which connects health innovation hubs globally to enhance drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and improving patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
Cambridge, United Kingdom
Founded
1913
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Flexible Work Hours
In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.
11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast
AstraZeneca unveils breakthrough data on vaccines and antibody therapies for infections.
AstraZeneca invested €365 million in expanding its production lines in Dunkirk.